Abstract:Background: To evaluate the characteristics of type 2 diabetes (T2DM) patients with or without chronic kidney disease (CKD) in Germany. Methods: Using combined DPV/DIVE registry data, the analysis included patients with T2DM at least ≥ 18 years old who had an estimated glomerular filtration rate (eGFR) value available. CKD was defined as an eGFR < 60 mL/min/1.73 m2 or eGFR ≥ 60 mL/min/1.73 m2 and albuminuria (≥ 30 mg/g). Median values of the most recent treatment year per patient are reported. Results: Among 343,675 patients with T2DM 171,930 had CKD. Patients with CKD had a median eGFR of 48.9 mL/min/1.73 m2 and 51.2% had a urinary albumin level ≥ 30 mg/g. They were older, had a longer diabetes duration and a higher proportion was females compared to patients without CKD (all p < 0.001). More than half of CKD patients (53.5%) were receiving long-acting insulin-based therapy versus around 39.1% of those without (p < 0.001). CKD patients also had a higher rate of hypertension (79.4% vs 72.0%; p < 0.001). The most common antihypertensive drugs among CKD patients were renin-angiotensin-aldosteron system inhibitors (angiotensin converting enzyme inhibitors 33.8%, angiotensin receptor blockers 14.2%) and diuretics (40.2%). CKD patients had a higher rate of dyslipidemia (88.4% vs 86.3%) with higher triglyceride levels (157.9 vs 151.0 mg/dL) and lower HDL-C levels (men: 40.0 vs 42.0 mg/dL; women: 46.4 vs 50.0 mg/dL) (all p < 0.001) and a higher rate of hyperkalemia (> 5.5 mmol/L: 3.7% vs. 1.0%). Comorbidities were more common among CKD patients (p < 0.001). Conclusion: The results illustrate the prevalence and morbidity burden associated with diabetic kidney disease in patients with T2DM in Germany. The data call for more attention to the presence of chronic kidney disease in patients with diabetes, should trigger intensified risk factor control up and beyond the control of blood glucose and HbA1c in these patients. They may also serve as a trigger for future investigations into this patient population asking for new treatment options to be developed.

Subklinische Pathologie der Koronararterien bei Typ-2-Diabetes und Albuminurie

Prevalence of macro- and microvascular complications in patients with type 2 diabetes and kidney disease with or without albuminuria in a single Chinese Diabetes Centre.

Clinical Significance of Determination of Serum Cystatin C,lipoprotein (α) and High Sensitivity C-reactive Protein in Type 2 Diabetic Patients with Early Renal Impairment.

Mikrovaskuläre Komplikationen bei Diabetes mellitus

Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases

Vascular pathologies in chronic kidney disease: pathophysiological mechanisms and novel therapeutic approaches

Therapieoptionen für chronische Nierenerkrankungen bei Typ-1-Diabetes

Ketonüberwachung identifiziert Personen mit Diabetes mit Risiko für Ketoazidose

Metabolites Potentially Derived from Gut Microbiota Associated with Podocyte, Proximal Tubule, and Renal and Cerebrovascular Endothelial Damage in Early Diabetic Kidney Disease in T2DM Patients

Cardiovascular risk due to diabetes mellitus in patients with chronic kidney disease-prospective data from the German Chronic Kidney Disease cohort

Risk of cardiovascular disease, death, and renal progression in diabetes according to albuminuria and estimated glomerular filtration rate

Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials

Practicalities and importance of assessing urine albumin excretion in type 2 diabetes: A cutting-edge update

Akutes Koronarsyndrom

Chronic kidney disease and associated cardiovascular risk factors in type 2 diabetes

Endothelial dysfunction markers syndecan-1 and thrombomodulin are associated with higher albuminuria levels in type 2 diabetes with no history of clinical cardiovascular disease

Making an impact on kidney disease in people with type 2 diabetes: the importance of screening for albuminuria

Clinical and Pathological Analysis of Type 2 Diabetic Patients with Kidney Injury

Natrium-Glukose-Cotransporter-2-Inhibitoren senken Risiko für Nephrolithiasis

Association between Albumin Alterations and Renal Function in Patients with Type 2 Diabetes Mellitus

Blutdrucksenkende Effekte beeinflussen Schutzfunktion neuer Antidiabetika